SEC Form 4 · accession 0000899243-16-019192

Coherus Oncology, Inc. · CHRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Technical Officer

Period of report

Nov 20, 2015

Accepted (ET)

May 4, 2016 · 4:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001512762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value	Nov 20, 2015	M	20,000	$1.417	A	20,000	I	By Wife
Common Stock, $0.0001 par value	Nov 20, 2015	S	20,000	$27.4089	D	0	I	By Wife
Common Stock, $0.0001 par value	May 2, 2016	M	1,493	$2.0838	A	1,493	I	By Wife
Common Stock, $0.0001 par value	May 2, 2016	S	1,493	$20.00	D	0	I	By Wife

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F2	$1.417	Nov 20, 2015	M	20,000	D	—	Nov 21, 2023	Common Stock	20,000	39,988	I
Stock Option (right to buy)^F3	$2.0838	May 2, 2016	M	1,493	D	—	Feb 27, 2023	Common Stock	1,493	55,495	I

F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person's wife.
F2A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 30, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F3A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from June 4, 2012, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date